文献速递心脑血管急症

缺血性卒中后72小时内双联抗血小板治疗

Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke.
PubMed 文献 · N Engl J Med · 2023-01-01
一句话结论推定动脉粥样硬化性轻型缺血性卒中或高危TIA,72小时内启动氯吡格雷联合阿司匹林较单用阿司匹林降低90天新发卒中风险(7.3% vs 9.2%,HR 0.79),但中重度出血风险升高(0.9% vs 0.4%,HR 2.08)。

INSPIRES为在中国222家医院开展的双盲、随机、安慰剂对照、2×2析因试验,纳入未溶栓或取栓的轻型缺血性卒中或推定动脉粥样硬化性高危TIA患者,症状发作72小时内按1:1随机分配至氯吡格雷(第1天300 mg,第2–90天75 mg每日)联合阿司匹林(第1天100–300 mg,第2–21天100 mg每日)组或匹配氯吡格雷安慰剂联合阿司匹林(第1天100–300 mg,第2–90天100 mg每日)组。共6100例患者入组,每组3050例;13.1%以TIA为入组事件,12.8%在卒中发作≤24小时内被分配至治疗组,87.2%在发作后>24小时且≤72小时内被分配。主要疗效终点90天内新发卒中在氯吡格雷-阿司匹林组222例(7.3%)、阿司匹林组279例(9.2%)(HR 0.79;95%CI 0.66–0.94;P=0.008);主要安全终点中重度出血分别为27例(0.9%)与13例(0.4%)(HR 2.08;95%CI 1.07–4.04;P=0.03)。

要点

  • 推定动脉粥样硬化性轻型缺血性卒中或高危TIA,未溶栓或取栓,症状发作72小时内启动氯吡格雷联合阿司匹林,90天新发卒中7.3% vs 单用阿司匹林9.2%(HR 0.79;95%CI 0.66–0.94;P=0.008)。
  • 同一人群中,氯吡格雷联合阿司匹林90天内中重度出血0.9% vs 单用阿司匹林0.4%(HR 2.08;95%CI 1.07–4.04;P=0.03)。
  • 方案为氯吡格雷第1天300 mg、第2–90天75 mg每日,联合阿司匹林第1天100–300 mg、第2–21天100 mg每日;对照为匹配氯吡格雷安慰剂联合阿司匹林第1天100–300 mg、第2–90天100 mg每日。
  • 入组患者中13.1%以TIA为入组事件;12.8%在卒中发作≤24小时内被分配至治疗组,87.2%在>24小时且≤72小时内被分配。
  • 该析因试验中双联抗血小板部分与即刻对比延迟他汀治疗部分无交互作用(他汀部分未在本报告内)。

适用人群与场景

  • 中国222家医院中,未接受溶栓或取栓的轻型缺血性卒中或推定动脉粥样硬化性高危TIA患者,症状发作72小时内入组。
  • 12.8%的患者在卒中发作≤24小时内被分配至治疗组,87.2%在>24小时且≤72小时内被分配。
  • 13.1%的患者以TIA为入组事件。

处置流程与药物剂量

  • 氯吡格雷-阿司匹林组:氯吡格雷第1天300 mg,第2–90天75 mg每日;阿司匹林第1天100–300 mg,第2–21天100 mg每日。
  • 对照(阿司匹林)组:匹配氯吡格雷安慰剂;阿司匹林第1天100–300 mg,第2–90天100 mg每日。
  • 治疗在症状发作72小时内启动,按1:1随机分配。

研究设计与关键结果

  • 双盲、随机、安慰剂对照、2×2析因试验,中国222家医院,共6100例患者入组,每组3050例。
  • 主要疗效终点(90天内新发卒中):氯吡格雷-阿司匹林组222例(7.3%)vs 阿司匹林组279例(9.2%),HR 0.79(95%CI 0.66–0.94),P=0.008。
  • 主要安全终点(90天内中重度出血):氯吡格雷-阿司匹林组27例(0.9%)vs 阿司匹林组13例(0.4%),HR 2.08(95%CI 1.07–4.04),P=0.03。
  • 双联抗血小板部分与即刻对比延迟他汀治疗部分无交互作用;他汀部分未在本报告中报告。

证据类型、等级与局限

  • 证据类型:双盲、随机、安慰剂对照、2×2析因试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对推定动脉粥样硬化性轻型缺血性卒中或高危TIA、未溶栓或取栓且症状发作72小时内的患者,氯吡格雷联合阿司匹林较单用阿司匹林降低90天新发卒中风险(7.3% vs 9.2%,HR 0.79;95%CI 0.66–0.94;P=0.008)。
  • 同一方案伴随中重度出血风险升高(0.9% vs 0.4%,HR 2.08;95%CI 1.07–4.04;P=0.03),决策时需同时权衡卒中复发与出血风险。

指南或共识出处

  • INSPIRES试验,ClinicalTrials.gov注册号NCT03635749,由(中国)国家自然科学基金等资助,发表于N Engl J Med。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Dual antiplatelet treatment has been shown to lower the risk of recurrent stroke as compared with aspirin alone when treatment is initiated early (≤24 hours) after an acute mild stroke. The effect of clopidogrel plus aspirin as compared with aspirin alone administered within 72 hours after the onset of acute cerebral ischemia from atherosclerosis has not been well studied.

METHODS: In 222 hospitals in China, we conducted a double-blind, randomized, placebo-controlled, two-by-two factorial trial involving patients with mild ischemic stroke or high-risk transient ischemic attack (TIA) of presumed atherosclerotic cause who had not undergone thrombolysis or thrombectomy. Patients were randomly assigned, in a 1:1 ratio, within 72 hours after symptom onset to receive clopidogrel (300 mg on day 1 and 75 mg daily on days 2 to 90) plus aspirin (100 to 300 mg on day 1 and 100 mg daily on days 2 to 21) or matching clopidogrel placebo plus aspirin (100 to 300 mg on day 1 and 100 mg daily on days 2 to 90). There was no interaction between this component of the factorial trial design and a second part that compared immediate with delayed statin treatment (not reported here). The primary efficacy outcome was new stroke, and the primary safety outcome was moderate-to-severe bleeding - both assessed within 90 days.

RESULTS: A total of 6100 patients were enrolled, with 3050 assigned to each trial group. TIA was the qualifying event for enrollment in 13.1% of the patients. A total of 12.8% of the patients were assigned to a treatment group no more than 24 hours after stroke onset, and 87.2% were assigned after 24 hours and no more than 72 hours after stroke onset. A new stroke occurred in 222 patients (7.3%) in the clopidogrel-aspirin group and in 279 (9.2%) in the aspirin group (hazard ratio, 0.79; 95% confidence interval [CI], 0.66 to 0.94; P = 0.008). Moderate-to-severe bleeding occurred in 27 patients (0.9%) in the clopidogrel-aspirin group and in 13 (0.4%) in the aspirin group (hazard ratio, 2.08; 95% CI, 1.07 to 4.04; P = 0.03).

CONCLUSIONS: Among patients with mild ischemic stroke or high-risk TIA of presumed atherosclerotic cause, combined clopidogrel-aspirin therapy initiated within 72 hours after stroke onset led to a lower risk of new stroke at 90 days than aspirin therapy alone but was associated with a low but higher risk of moderate-to-severe bleeding. (Funded by the National Natural Science Foundation of China and others; INSPIRES ClinicalTrials.gov number, NCT03635749.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Gao Y, Chen W, Pan Y, et al. Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke. N Engl J Med. 2023. PMID: 38157499. doi:10.1056/NEJMoa2309137

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。